Loading, Please Wait...
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the second quarter and six months ended June 30, 2019 and provided a corporate update.
“I am pleased with the exciting progress Harpoon has made so far in 2019 with two T cell engagers, HPN424 and HPN536, in the clinic as planned,” said Gerald McMahon, Ph.D., President and Chief Executive Officer of Harpoon Therapeutics. “The dose escalation portion of the clinical trial for our lead product candidate, HPN424, continues to advance and we expect to present an interim dataset during the first half of 2020 at an appropriate medical meeting. Our confidence in our TriTAC platform continues to solidify as we learn more about its capabilities and promise.”
“Consistent with the TriTAC mechanism of action, we observed T cell activation and cytokine induction with HPN424 treatment, which prompted us to explore the use of dexamethasone as a premedication to limit potential adverse events,” said Natalie Sacks, M.D., Chief Medical Officer of Harpoon Therapeutics. “We have found that the addition of weekly dexamethasone premedication, tapered over several weeks, has successfully limited adverse events. When patients completed the scheduled taper, they continued to receive weekly HPN424, without dexamethasone, with no complications observed thus far. This strategy has allowed us to proceed with dose escalations of HPN424 and further advance this promising potential therapy.”
Second Quarter 2019 Business Highlights and Other Recent Developments
Anticipated Milestones
Second Quarter Financial Results
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC™) platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.
Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “target,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon Therapeutics’ clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the timing of IND submissions, the progress, timing, scope and anticipated results of clinical trials, the timing of the presentation of data, the association of data with potential treatment outcomes, the development and advancement of product candidates, and the timing of development milestones for product candidates. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause Harpoon Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics’ filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Harpoon Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Contacts:
Harpoon Therapeutics, Inc.
Georgia Erbez
Chief Financial Officer
media@harpoontx.com
Westwicke ICR
Robert H. Uhl
Managing Director
858-356-5932
robert.uhl@westwicke.com
Harpoon Therapeutics, Inc.
Statement of Operations and Comprehensive Loss
(Unaudited)
(in thousands, except share and per share amounts)
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2019 | 2018 | 2019 | 2018 | |||||||||||||
Revenue | ||||||||||||||||
Collaboration and license revenue | $ | 1,063 | $ | 1,063 | $ | 2,126 | $ | 2,626 | ||||||||
Total revenue | 1,063 | 1,063 | 2,126 | 2,626 | ||||||||||||
Operating expenses | ||||||||||||||||
Research and development | 9,971 | 6,151 | 19,353 | 11,684 | ||||||||||||
General and administrative | 3,734 | 967 | 9,566 | 1,949 | ||||||||||||
Total operating expenses | 13,705 | 7,118 | 28,919 | 13,633 | ||||||||||||
Loss from operations | (12,642 | ) | (6,055 | ) | (26,793 | ) | (11,007 | ) | ||||||||
Interest income | 840 | 66 | 1,416 | 139 | ||||||||||||
Other expense | (15 | ) | (5 | ) | (19 | ) | (7 | ) | ||||||||
Net loss | (11,817 | ) | (5,994 | ) | (25,396 | ) | (10,875 | ) | ||||||||
Other comprehensive loss: | ||||||||||||||||
Net unrealized gain on marketable securities | 84 | — | 110 | — | ||||||||||||
Comprehensive loss | $ | (11,733 | ) | $ | (5,994 | ) | $ | (25,286 | ) | $ | (10,875 | ) | ||||
Net loss per share, basic and diluted | $ | (0.49 | ) | $ | (5.89 | ) | $ | (1.30 | ) | $ | (10.95 | ) | ||||
Weighted-average shares used in computing net loss per share, basic and diluted | 24,294,211 | 1,017,336 | 19,548,600 | 993,418 |
Harpoon Therapeutics, Inc.
Selected Balance Sheet Data
(Unaudited)
June 30, 2019 | December 31, 2018 | |||||||
(in thousands) | ||||||||
Assets: | ||||||||
Cash, cash equivalents, and marketable securities | $ | 133,884 | $ | 89,493 | ||||
Total assets | 157,016 | 102,580 | ||||||
Total liabilities | 34,543 | 26,482 | ||||||
Total convertible preferred stock | — | 129,577 | ||||||
Total stockholders' equity (deficit) | 122,473 | (53,479 | ) |